Oncology

Abraxane treats patients with advanced, squamous non-small cell lung cancer (NSCLC).

With recent therapeutic advances, the treatment landscape for metastatic castration-resistant prostate cancer is changing rapidly.

Durvalumab and tremelimumab was active in patients with or without tumor expression of PD-L1 in NSCLC.

Nanoparticles acting as cancer drug delivery vehicles show promise in eliminating tumors.

Medication spending waste can be reduced with smaller vials of cancer drugs, study finds.

High cost infused cancer drugs are packaged containing quantities larger than needed to treat patients.

Adherence patterns and other risk factors predict increased utilization of acute care by outpatients with cancer pain.

Controversy swirls around the naming protocol for biosimilars among drug manufacturers and the FDA.

Men diagnosed with cancer under age 25 far less likely to have children and more likely to take infertility drugs.

Less than half of adolescents and young adults who survive Hodgkin lymphoma receive recommended services within the first year after treatment.

Combination of sialidase and cucurbitacin I shows substantial antitumor activity in sarcoma therapy.

The combined impact of anti-cancer treatments and exercise holds promise for shrinking tumors.

Recent advances and updates in oncology and cancer drug development.

Catch up with the latest developments across the health care landscape and sign up for key upcoming conferences.

Everolimus (Afinitor) treats progressive, non-functional neuroendocrine tumors of gastrointestinal or lung origin.

Everolimus (Afinitor) treats progressive, non-functional neuroendocrine tumors of gastrointestinal or lung origin.

Gazyva plus bendamustine provides a new option to significantly reduce the risk of death.

The management of individual chemotherapy regimens by pharmacists improves safety by reducing medication errors.

FDA approval for Gazyva gives new option to patients with follicular lymphoma who did not respond to a regimen containing rituximab (Rituxan).

Early lineage T cells show promise in the treatment of acute lymphoblastic leukemia.

Interferon therapy not recommended for patients with minimal cancer in one lymph node.

Jury orders Johnson & Johnson to pay $72 million in damages to the family of a woman who died from ovarian cancer allegedly caused by products containing talcum powder.

Proposal includes giving insurers the ability to withhold products from formularies if the cost of cancer drugs do not represent good value.

Study finds cancer patients need better support following treatment.

Enzalutamide (Xtandi) capsules treats patients with metastatic castration-resistant prostate cancer.

Dasatinib and demcizumab reduces lung adenocarcinomas and improves survival rates in lung cancer treatment.

Nanoparticle designed to directly hit tumors with a toxic cancerous drug without harming healthy tissue.

Palbociclib (Ibrance) approved for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.